OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 14.63 |
| Open | 14.57 |
| Bid | 6.00 x 800 |
| Ask | 15.05 x 800 |
| Day's Range | 13.98 - 14.86 |
| 52 Week Range | 5.15 - 51.90 |
| Volume | 23,332 |
| Avg. Volume | 23,423 |
| Market Cap | 40.08M |
| Beta | -0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.48 |
| Earnings Date | Mar 14, 2018 - Mar 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.00 |
- GlobeNewswire•11 days ago
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry. With his appointment, the Opiant Board now consists of six members, four of whom are independent.
- GlobeNewswire•19 days ago
Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will participate in a panel at the BIO International Convention, being held June 4-7, 2018, in Boston, Massachusetts. The panel, which takes place on Tuesday, June 5, 2018, at 11:00 AM ET, will focus on understanding the biology underlying pain and addiction that are critical to supporting the discovery of novel and safer treatments for both pain and addiction, as well as for ensuring that patients receive the right treatment at the right time, with the right support, and without stigma.
- GlobeNewswire•25 days ago
Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, and Phil Skolnick, Ph.D., Opiant’s Chief Scientific Officer, will participate in a panel session at the American Society of Clinical Psychopharmacology (ASCP) 2018 Annual Meeting, being held May 29 – June 1, 2018, in Miami Beach, Florida. Dr. Skolnick will chair a panel session, titled: “The Opioid Epidemic: Crisis and Solutions,” and Dr. Crystal will be a speaker on the panel. Additionally, ASCP will present the 2018 “Donald Klein Lifetime Achievement Award” to Dr. Skolnick for his contributions to the field of neuropsychopharmacology. Prior to his current role as Chief Scientific Officer of Opiant, Dr. Skolnick served as the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, National Institutes of Health.
- GlobeNewswire•29 days ago
Report: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, May 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Opiant ...
- Zacks Small Cap Research•last month
OPNT: KOL Event Highlights Medications for Addictions and Related Disorders
Dr. Comer is a Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons at Columbia University. Dr. Comer began her talk with an overview of the epidemiology of the opioid epidemic. The following graphic shows the startling increase in drug overdose deaths from 1999 to 2016.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 08, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first ...
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, will host a Key Opinion Leader (KOL) luncheon on Medications for Addictions and Related Disorders on Thursday, May 10 in New York City. The event will feature presentations by KOLs Sandra Comer, PhD, Columbia University, Susan McElroy, MD, University of Cincinnati, and Stephanie O'Malley, PhD, Yale School of Medicine, who will discuss the current treatment landscape and unmet medical need for treating patients with substance use and eating disorders.
- ACCESSWIRE•2 months ago
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT) ("Opiant"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPNT as the Company's latest news hit the wire. On April 18, 2018, the Company, which is a specialty pharmaceutical organization developing pharmacological treatments for addictions, declared that the National Institutes of Health's National Institute on Drug Abuse (NIDA) has granted it an award of approximately $7.4 million for the development of OPNT003 (intranasal nalmefene) for opioid overdose.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. “We view this NIDA grant as further validation of the potential for OPNT003 to be an important treatment for opioid overdose, a growing U.S. health epidemic,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Fentanyl was responsible for more overdose deaths (in excess of 20,000) than either heroin or prescription opioids in 2016. Recognizing the evolution of the opioid crisis, the National Institutes of Health has called for the development of stronger, longer-acting overdose reversal products in order to address this next wave of potent synthetic opioids, like fentanyl.
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, April 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•3 months ago
Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates
Stock Monitor: Opiant Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free earnings report on HubSpot, Inc. (NYSE: HUBS ). If you want ...
- Zacks Small Cap Research•3 months ago
OPNT: Opiant Developing New Opioid Overdose Treatment
As part of the solution to the problem, the CDC recommends that the federal government “improve access to…overdose-reversing drugs, such as naloxone” and that health departments “increase naloxone distribution to first responders, family and friends, and other community members in affected areas” (CDC). While not a treatment for opioid dependence, health authorities believe that easy access to naloxone is an essential component of battling the ongoing opioid crisis due to its effectiveness in preventing overdose deaths. On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment.
- Reuters•3 months ago
Trump says he is working to lower prescription drug prices
President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. "If you compare our drug prices to other countries in the world, in some cases it's many times higher for the exact same pill or whatever it is, in the exact same package made in the exact same plant," Trump said. Trump made the remarks during a speech in Manchester, New Hampshire that focused on the administration's efforts to battle the nation's opioid addiction crisis.
- Reuters•3 months ago
As U.S. opioid crisis grows, Trump calls for death penalty for dealers
President Donald Trump spelled out in new detail several steps he favors to fight a U.S. epidemic of opioid abuse, including the execution of drug dealers, a proposal that has gained little support from drug abuse and judicial experts. At an event in Manchester, New Hampshire, Trump unveiled an anti-opioid abuse plan, including his death penalty recommendation, new funding for other initiatives and stiffer sentencing laws for drug dealers.
- Zacks Small Cap Research•4 months ago
OPNT: Developing Longer-Acting Opioid Overdose Treatment
On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT003 is an intranasal formulation of nalmefene, a naltrexone derivative. The U.S. continues to battle an opioid epidemic.
Associated Press•6 months agoInsider Q&A: Narcan exec talks merits of spray for overdoses
Dr. Roger Crystal's company was struggling to find new uses for an old drug that reverses overdoses. Then the opioid epidemic hit. Naloxone had first gone on sale in 1971 but was injected with a syringe. ...
- Zacks Small Cap Research•6 months ago
OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18
On December 20, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced that it expects to begin receiving 90% of royalty and milestone payments related to the sale of NARCAN® Nasal Spray beginning in the first quarter of 2018. On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones were met.